BioAtla Results Presentation Deck

Oo Stage IV Multi-Refractory Melanoma: Phase 1 & 2 Complete Response Observed in Two of Two ROR2+ Patients Phase 1/2 - MELANOMA Data on file. % Change in Target Lesions from Baseline 100 80 60 40 20 0 -20 -40 -60 -80 -100 0 Phase 2 Patient Details: Prior treatment failure: nivolumab followed by Dacarbazine ✓ Complete Response on 1st scan (3 doses) 20 ROR2 + Phase 2 Patient 40 60 80 Time (weeks) 100 120 140 Phase 1 Patient Details: ✓ Prior treatment failure: nivolumab followed by nivolumab + ipilimumab combination Clearance of pulmonary metastases followed by normalization of adenopathy Continued CR Off treatment for over 2 yrs ROR2 + Phase 1 Patient bicatla 160 Ozuriftamab vedotin - BA3021 7

View entire presentation